Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Methods in Molecular Medicine
|
February 22, 2011
Engineering antibody molecules
R Verma, E Boleti
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2006
ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors
E Boleti, G M Mead
Hematological Oncology
|
June 19, 2007
Primary mediastinal B-cell lymphoma
E Boleti, P W M Johnson
Journal of Immunological Methods
|
October 6, 1998
Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems
R Verma, E Boleti, A J George
Biochemical Society Transactions
|
November 1, 1995
Therapeutic monoclonals
E Boleti, A J George, A A Epenetos
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 1, 1995
Construction, expression and characterisation of a single chain anti-tumour antibody (scFv)-IL-2 fusion protein
E Boleti, M P Deonarain, R A Spooner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2013
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer
T Powles, I Kayani, K Sharpe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2016
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
T Powles, J Brown, J Larkin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2025
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
L Bergmann, L Albiges, M Ahrens, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Methods in Molecular Medicine
|
February 22, 2011
Engineering antibody molecules
R Verma, E Boleti
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 31, 2006
ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors
E Boleti, G M Mead
Hematological Oncology
|
June 19, 2007
Primary mediastinal B-cell lymphoma
E Boleti, P W M Johnson
Journal of Immunological Methods
|
October 6, 1998
Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems
R Verma, E Boleti, A J George
Biochemical Society Transactions
|
November 1, 1995
Therapeutic monoclonals
E Boleti, A J George, A A Epenetos
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 1, 1995
Construction, expression and characterisation of a single chain anti-tumour antibody (scFv)-IL-2 fusion protein
E Boleti, M P Deonarain, R A Spooner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2013
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer
T Powles, I Kayani, K Sharpe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 24, 2016
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
T Powles, J Brown, J Larkin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 3, 2025
Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
L Bergmann, L Albiges, M Ahrens, et al.
Page
of 1